Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy: a Randomized Non-comparative Two-arm Phase II Study

NCT03704480 is registered in ClinicalTrials.gov with GERCOR - Multidisciplinary Oncology Cooperative Group as lead sponsor.

NCT NCT03704480
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03704480 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy: a Randomized Non-comparative Two-arm Phase II Study
Lead sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 9, 2018
Completion date
December 31, 2025
Enrollment
106 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

advanced biliary tract carcinoma